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ative Group of the Spanish Society of
Pneumology and Thoracic Surgery.
To classify as pathologic (p) N2 a
tumor that has not been resected, even if
there is pathologic confirmation of the
metastatic nature of the lymph nodes by
means of any preoperative endoscopy
(transbronchial needle aspiration, ultra-
sonography-assisted bronchoscopy, or
oesophagoscopy with fine needle aspira-
tion), percutaneous needle aspiration, or
surgical exploration (mediastinoscopy,
mediastinotomy, extended cervical me-
diastinoscopy, or thoracoscopy) goes
against general rule 2 of the tumor (T),
node (N), metastasis (M) classification
of malignant tumors, which says “Clin-
ical classification (. . .) is based on evi-
dence acquired before treatment. Such
evidence arises from physical examina-
tion, imaging, endoscopy, biopsy, surgi-
cal exploration, and other relevant ex-
aminations.”2 “Pathologic classification
(. . .) is based on the evidence acquired
before treatment, supplemented or mod-
ified by the additional evidence acquired
from surgery and from pathologic exam-
ination (. . .)” and “entails a resection of
the primary tumor or biopsy adequate to
evaluate the highest pT category (. . .)”
and “the removal of nodes (. . .).” “An
excisional biopsy alone of a lymph node
without pathologic assessment of the
primary is insufficient to fully evaluate
the pN category and is a clinical classi-
fication (. . .).”2
Back, at least, to the early 1990s,
some chest physicians and oncologists,
mainly in North America, started to
think that pathologic confirmation of tu-
mor extent in the pretreatment assess-
ment of lung cancer entitled them to
assign a pathologic classification to
these tumors. This is an evident misin-
terpretation of the word “pathologic” in
the context of the TNM classification
and a violation of the general rule 2.
This misinterpretation eventually found
its way into medical writing, as we
pointed out in 2004.3 Now, 5 years later,
this schismatic use of the “p” prefix
seems to be explicitly sanctioned by the
International Association for the Study
of Lung Cancer.
There are important implications
associated with this misunderstanding
that go beyond mere taxonomy. Accord-
ing to the general rules, even if a cyto-
histologically diagnosed tumor has
pathologic evidence of nodal disease, its
classification will still be clinical by def-
inition, because the tumor has not been
resected. If we assign “p” status to tu-
mors that have not been resected, we
will be mixing tumors with very differ-
ent prognosis, i.e., tumors with patho-
logic confirmation of their anatomic ex-
tent but that do not undergo resection
and tumors that have been resected and
have a proper pathologic classification.
The Certainty Factor4 offers the possi-
bility to code in a different way those
nodes considered involved by imaging
methods and by pathologic confirmation
in the clinical phase of the tumor clas-
sification without relying to the “p” pre-
fix, which should be reserved for patho-
logic classification, only.
In conclusion, assigning “p” status
to unresected tumors that have pathologic
confirmation of their nodal extent goes
against general rule 2 of the TNM classi-
fication; it produces a mixture of cases of
different prognosis that undermines the
prognostic capacity of the TNM classifi-
cation for lung cancer gained by the revi-
sions that lead to its 7th edition, and there-
fore, it should be avoided.
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In Response:
We are grateful to the editor for
an opportunity to respond to this ques-
tion, which it is proposed to publish in
the Journal of Thoracic Oncology. We
should emphasize that the chapters in
the IASLC Manual on Thoracic Stag-
ing1 to which the comments are ad-
dressed, and many other chapters in
this book, and the companion IASLC
Handbook of Staging in Thoracic On-
cology,2 were reproduced with the per-
mission of the International Union
Against Cancer from publications to
be published later this year: the TNM
Classification of Malignant Tumors
7th edition and the TNM Supplement:
A Commentary on Uniform Use 4th
edition. Fuller explanatory notes will
be available in these publications.
The International Association for
the Study of Lung Cancer was accorded
the privilege of publishing these chap-
ters ahead of the source material because
of its central role in formulating the
proposals for the 7th edition and delays
in the publishing schedules of the Inter-
national Union Against Cancer and the
American Joint Committee on Cancer,
the two bodies that administer the tu-
mor, node, metastasis (TNM) classifica-
tion worldwide. In no sense was it the
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TABLE 1. Frequently Asked Question and Answer1
Question Clinical classification suggested that our patient had a T2 N2 M0 NSCLC. Preoperative
biopsy of ipsilateral mediastinal nodes confirmed N2 disease, and a thoracotomy was
not undertaken. Should this case be classified as cN2 or pN2? Should this case now
be assigned a pathologic stage?
Answer Microscopic confirmation of the nodal disease would allow this to be classified as pN2.
However, to be designated a pathologic stage, the primary tumor must also have
been confirmed on biopsy to establish the pT category.
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intention of the International Associa-
tion for the Study of Lung Cancer to
presume to “sanction” the authority of
these publications.
The central question raised in the
letter by Lopez-Encuentra et al. asks
whether it is ever appropriate to use
the “p” descriptor in association with
(a) a TNM classification or stage or (b)
a T, N, or M category, in cases in
which resection has not been per-
formed. They accurately quote Gen-
eral Rule 2, and in practice, a pTNM
classification or pStage is most com-
monly applied when describing the ex-
tent of disease after surgical resection
and pathologic examination e.g. pT3
N2 M0, pStage IIIA. Although in this
situation the “pT” category will have
been assigned on the basis of a high
level of certainty, C4, and it is usual to
afford the same level of certainty to
the “pN” category, the “M0” category
is always assumed on the basis of the
clinical classification, with a Certainty
factor of C1 or C2. Some would fur-
ther question whether it is appropriate
to assign a “pN” category after resec-
tion in cases in which the N3 nodes
have not been thoroughly evaluated or
in which the assessment of pN0 has
been based on a casual assessment of
the ipsilateral nodes in N1 and/or N2
locations. In this edition of TNM, we
have sought to address the latter by
reinstating a minimum number of
lymph nodes expected to assure pN0
and have suggested that an “R1(un)”
classification be trialed for cases,
which are designated pN0 on less ro-
bust evidence.
There are circumstances in
which surgical treatment is inappropri-
ate and yet a higher Certainty factor,
C3, has been achieved in the patho-
logic confirmation of the T, N, or M
category. Surgical procedures such a
mediastinoscopy have traditionally
been accorded a specificity of 100%.
We are fortunate that an expanding
armamentarium is now available in
thoracic oncology, which allows us to
assess nodal status by less invasive
procedures, such as endobronchial ul-
trasound and endoscopic ultrasound,
with a similarly high specificity. It is
therefore not illogical to assign a pN
category in such circumstances.
Although General Rules must re-
main inviolable, it is surely appropri-
ate that their interpretation evolves as
the science of oncology improves. In-
deed, in the TNM Supplement: A com-
mentary on Uniform Use,3 on page 97,
the Site specific Recommendations for
pT and pN in Lung and Pleural Tu-
mors requires only the “Microscopic
confirmation of metastasis” when as-
signing a pN category.
We accept that the N2 case illus-
trated in the Frequently Asked Ques-
tions in Chapter 121 will have a different
prognosis to one in which a pN2 cate-
gory is assigned after surgical resection,
usually in cases in which a cN0 or cN1
category had been assigned prior to tho-
racotomy. However, this could be re-
lated to the different treatments appro-
priate in these scenaria or the reduced
performance status that could weigh
against surgery in some situations. Al-
though the anatomic extent of disease,
as described by the TNM classification,
remains the single most important prog-
nostic factor, the surest way to ensure
homogeneity within any study popula-
tion is to collect data on as many prog-
nostic factors as possible.
We hope that this clarifies the
situation.
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The Mesothelioma and
Radical Surgery
Feasibility Study
To the Editor:
As Chair of the Trial Steering
Committee for the mesothelioma and
radical surgery trial, I was pleased to
see the preliminary results of this
study published in the Journal of Tho-
racic Oncology,1 with the positive as-
pects of the trial emphasized in an
accompanying editorial by Dr. Rusch.2
However, one should note that the
original trial design required the ran-
domization of 50 cases in 1 year, and
not the 3 plus years that proved nec-
essary to achieve this accrual. Given
the high incidence of malignant pleu-
ral mesothelioma in the United King-
dom and the organizational advantages
in this county, emphasized in the edi-
torial, this does suggest that those who
expressed concern as to the feasibility
of this randomization, mentioned in
the Discussion, were not completely
wrong! I raise this issue, as it must
have a profound impact on the ques-
tion to be posed in any follow-up
study, an issue on which the authors of
the article, and the editorial seem to
hold differing opinions.
Peter Goldstraw, MB, FRCS
Department of Thoracic Surgery
Royal Brompton Hospital
London, United Kingdom
Department of Thoracic Surgery
Imperial College
London, United Kingdom
REFERENCES
1. Treasure T, Waller D, Tan C, et al. The
mesothelioma and radical surgery randomized
controlled trial: the MARS feasibility study.
J Thorac Oncol 2009;4:1254–1258.
2. Rusch VW. The MARS trial: resolution of
the surgical controversies in mesothelioma?
J Thorac Oncol 2009;4:1189–1191.
Disclosure: The author declares no conflicts of
interest.
Address for correspondence: Peter Goldstraw, MB,
FRCS, Royal Brompton Hospital, Sydney St,
London Sw3 6NP, United Kingdom. E-mail:
P.Goldstraw@rbht.nhs.uk
Copyright © 2010 by the International Association
for the Study of Lung Cancer
ISSN: 1556-0864/10/0502-0287
Journal of Thoracic Oncology • Volume 5, Number 2, February 2010 Letter to the Editor
Copyright © 2010 by the International Association for the Study of Lung Cancer 287
